Research progress on the mechanism of traditional Chinese medicine regulating metabolic reprogramming to improve breast cancer
- VernacularTitle:中药调控代谢重编程改善乳腺癌的作用机制研究进展
- Author:
Zhenyu ZHANG
1
;
Weixia CHEN
2
;
Bo FENG
2
;
Jilei LI
2
;
Sizhe WANG
3
;
Meng ZHU
3
;
Chunzheng MA
2
Author Information
1. Dept. of Oncology，Henan Provincial Hospital of Chinese Medicine/the Second Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450002，China;The Second Clinical Medical College，Henan University of Chinese Medicine，Zhengzhou 450046，China
2. Dept. of Oncology，Henan Provincial Hospital of Chinese Medicine/the Second Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450002，China
3. The Second Clinical Medical College，Henan University of Chinese Medicine，Zhengzhou 450046，China
- Publication Type:Journal Article
- Keywords:
breast cancer;
metabolic reprogramming
- From:
China Pharmacy
2026;37(2):250-256
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic reprogramming， as one of the core hallmarks of malignant tumors， plays a key role in the occurrence， development and treatment of breast cancer （BC）. Abnormal changes in glucose metabolism， amino acid metabolism， lipid metabolism， as well as the tricarboxylic acid （TCA） cycle and oxidative phosphorylation （OXPHOS） pathways significantly influence the pathogenesis and progression of BC. Studies have shown that various active components of traditional Chinese medicine （TCM） （such as berberine， matrine， quercetin， curcumin， etc.） and their compound formulations （e.g. Xihuang pill， Danzhi xiaoyao powder， Yanghe decoction， etc.） can inhibit the proliferation and migration of BC cells and induce apoptosis by regulating key metabolic pathways such as glycolysis， lipid synthesis， and amino acid metabolism. TCM demonstrates multi-target and holistic regulatory advantages in intervening in BC metabolic reprogramming， showing significant potential in modulating key molecules like hypoxia inducible factor-1α， hexokinase-2， pyruvate kinase M2， lactate dehydrogenase A， glucose transporter-1， fatty acid synthase， and signaling pathways such as AKT/mTOR. However， current researches still focus predominantly on glucose metabolism， with insufficient mechanistic studies on lipid metabolism， amino acid metabolism， the TCA cycle， and OXPHOS. The precise targets， molecular mechanisms， and clinical translation value of these interventions require further validation and clarification through more high-quality experimental studies and clinical trials.
